Featured Press Releases

ImmPACT Bio announces FDA clearance of its IND application for CD19/CD20 bispecific CAR-T cell therapy in multiple sclerosis

ImmPACT Bio announces FDA clearance of its IND application for CD19/CD20 bispecific CAR-T cell therapy in multiple sclerosis

Viatris announces the approval of the first generic iron sucrose injection in the U.S

Viatris announces the approval of the first generic iron sucrose injection in the U.S

  • 11 Aug 2025

Viatris Inc. a global healthcare company, announced the U.S. Food and Drug Administration (FDA)...

BeiGene highlights TEVIMBRA® data in lung and gastrointestinal cancers

BeiGene highlights TEVIMBRA® data in lung and gastrointestinal cancers

Molecular Residual Disease and Liquid Biopsy Solutions Launched by Labcorp

Molecular Residual Disease and Liquid Biopsy Solutions Launched by Labcorp

Samsung Epis Holdings, Newly Established, to Drive Growth for Samsung Bioepis and Its New Subsidiary

Samsung Epis Holdings, Newly Established, to Drive Growth for Samsung Bioepis and Its New Subsidiary

Unique Mouse Model Enables genOway to Transform Prediction of Antibody Therapies in Humans

Unique Mouse Model Enables genOway to Transform Prediction of Antibody Therapies in Humans

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of TECVAYLI + DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma.

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of TECVAYLI + DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma.

  • Johnson & Johnson
  • 06 Mar 2026
ulrich medical USA® Expands Commitment to Evidence-Based Spine Innovation; Appoints Alissa Calaway, RN, MSN as Director of U.S. Clinical Affairs

ulrich medical USA® Expands Commitment to Evidence-Based Spine Innovation; Appoints Alissa Calaway, RN, MSN as Director of U.S. Clinical Affairs

  • ulrich medical USA
  • 06 Mar 2026
Cognito Therapeutics Announces $105 Million Oversubscribed Series C Financing to Advance Spectris™ in Alzheimer’s Disease.

Cognito Therapeutics Announces $105 Million Oversubscribed Series C Financing to Advance Spectris™ in Alzheimer’s Disease.

  • Cognito Therapeutics
  • 05 Mar 2026
Eton Pharmaceuticals Strengthens Rare Disease Portfolio with U.S. Commercialization Rights to HEMANGEOL® Oral Solution

Eton Pharmaceuticals Strengthens Rare Disease Portfolio with U.S. Commercialization Rights to HEMANGEOL® Oral Solution

  • Eton Pharmaceuticals
  • 04 Mar 2026
FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

  • US-Rx
  • 03 Mar 2026
30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

  • Merck & Co., Inc.
  • 03 Mar 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
March   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.